Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood.2021014488
Abstract: CAPTIVATE (NCT02910583) is an international phase 2 study in patients aged ≤70 years with previously untreated chronic lymphocytic leukemia (CLL). Results from the cohort investigating fixed-duration treatment with ibrutinib plus venetoclax are reported. Patients received… read more here.
Keywords: ibrutinib plus; treatment; fixed duration; plus venetoclax ... See more keywords
Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia.
Sign Up to like & getrecommendations! Published in 2023 at "Blood"
DOI: 10.1182/blood.2022017333
Abstract: Activation of apoptosis in malignant cells is an established strategy for controlling cancer and is potentially curative. To assess the impact of concurrently inducing the extrinsic and intrinsic apoptosis-signaling pathways in acute myeloid leukemia (AML),… read more here.
Keywords: myeloid leukemia; plus venetoclax; eftozanermin alfa; acute myeloid ... See more keywords
Voruciclib plus venetoclax show high efficacy for CLL b cells on human stromal cells.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.e20009
Abstract: e20009Background: Although treating B-Chronic Lymphocytic Leukemia (CLL) with small molecule inhibitors has shown promise, a lasting cure for this disease has yet to be found. Further treatments di... read more here.
Keywords: cll; show high; venetoclax show; high efficacy ... See more keywords
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.21.00807
Abstract: PURPOSE CAPTIVATE (NCT02910583), a randomized phase II study, evaluates minimal residual disease (MRD)-guided treatment discontinuation following completion of first-line ibrutinib plus venetoclax treatment in patients with chronic lymphocytic leukemia (CLL). METHODS Previously untreated CLL patients… read more here.
Keywords: ibrutinib; plus venetoclax; treatment; ibrutinib plus ... See more keywords